{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-063143","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.813776+00:00","generated_at":"2026-06-14T18:16:57.287900+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avenue Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity","bullets":["Nasdaq notified Avenue Therapeutics on May 19, 2023, of non-compliance with minimum $2.5M stockholders' equity requirement.","Q1 2023 10-Q reported stockholders' equity of negative $2,157,000.","Company has 45 days (until July 3, 2023) to submit a plan to regain compliance.","No immediate effect on listing; stock continues trading on Nasdaq under ATXI.","Company intends to submit compliance plan and take measures to regain compliance, but no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-063143","json":"https://secwatch.observer/filing/0001104659-23-063143.json","markdown":"https://secwatch.observer/filing/0001104659-23-063143.md","text":"https://secwatch.observer/filing/0001104659-23-063143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923063143/0001104659-23-063143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923063143/tm2316427d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:16:57.287900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb1ed430a92181b453afe2b663c3a729ff9e2ede","claim":"AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"$2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, reported stockholders’ equity of negative $2,157,000. The Letter further noted that as of the letter date, the Company did not have a market value of listed securities of $35 million, or net income from continued operations of","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923063143/0001104659-23-063143-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}